Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 10/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CCR3 | P51677 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 3/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | KDM2B | Q8NHM5 | 3/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4022127 | 0.92 | KDM2B (0.39) | DRD4CYP2C9CYP2C19CCR3DRD2 | |
| SCHEMBL13721312 | 0.92 | KDM2B (0.39) | DRD4CYP2C9CYP2C19CCR3DRD2 | |
| SCHEMBL4023627 | 0.92 | KDM2B (0.39) | DRD4CYP2C9CYP2C19CCR3DRD2 | |
| SCHEMBL4023629 | 0.92 | KDM2B (0.39) | DRD4CYP2C9CYP2C19CCR3DRD2 | |
| SCHEMBL4021684 | 0.90 | KDM2B (0.38) | DRD4CYP2C9CYP2C19DRD2SMN1; SMN2 | |
| SCHEMBL4026436 | 0.88 | KDM2B (0.42) | DRD2THRBSMN1; SMN2RXFP1KDM2B | |
| SCHEMBL13721566 | 0.88 | DRD4 (0.42) | DRD4CYP2C9CYP2C19CCR3DRD2 | |
| SCHEMBL4022167 | 0.88 | DRD4 (0.42) | DRD4CYP2C9CYP2C19CCR3DRD2 | |
| SCHEMBL4022160 | 0.88 | DRD4 (0.42) | DRD4CYP2C9CYP2C19CCR3DRD2 | |
| SCHEMBL4020496 | 0.86 | DRD4 (0.34) | DRD4CYP2C9CYP2C19CCR3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572814-B2 | 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds | CYTOKINETICS, INCORPORATED (US) | 2009-08-11 | — | — | US | claimed |
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | claimed |
| US-7572814-B2 | 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds | CYTOKINETICS, INCORPORATED (US) | 2009-08-11 | — | — | US | disclosed |
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | TP53, VHL, RB1 | DRD4 2983/4885CYP2C9 3168/4885CYP2C19 2371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.